Boehringer's Spiriva inhaler now available throughout the U.S.; Update on Mannkind's inhaled insulin from JP Morgan;

> Boehringer Ingelheim's Spiriva Respimat inhaler is now available by prescription in pharmacies throughout the U.S. Release

> Mannkind's new CEO, Hakan Edstrom, gave an update on its inhaled insulin product at the JP Morgan Healthcare Conference. Afrezza is going to launch in partnership with Sanofi ($SNY). "In terms of the early market initiation, basically, we are looking at the insulin intensification of those patients that have been on a long acting initially to just avoid frequent injections and certainly those that are failing on orals and need to start an insulin therapy," he said. Listen

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.